Mylan demands payback from Strides on plants targeted by FDA

Mylan ($MYL) recently got hammered by the FDA in a warning letter for three plants that it acquired as part of its $1.75 billion acquisition of the sterile injectables business of what was then Strides Arcolabs. Now Mylan is apparently looking for Strides to cough up some of the cost of getting those plants back into shape. More from FiercePharmaManufacturing

Suggested Articles

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.

Months after trial deaths prompted the FDA to halt study enrollment for AbbVie’s Venclexta, the agency will give the drug another shot.